Overview of the Current Status of Human Epidermal Growth Factor Receptor Inhibitors in Lung Cancer

This publication has 58 references indexed in Scilit:

• A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1^st line or 2^nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial
  Journal of Clinical Oncology, 2004
• Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
  Journal of Clinical Oncology, 2004
• Pemetrexed for treatment of advanced non-small cell lung cancer
  Seminars in Oncology, 2004
• Cancer Statistics, 2004
  CA: A Cancer Journal for Clinicians, 2004
• Estimates of the world‐wide prevalence of cancer for 25 sites in the adult population
  International Journal of Cancer, 2001
• Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials
  Seminars in Oncology, 2001
• Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2000
• Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
  Journal of Clinical Oncology, 2000
• Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2000
• Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
  Journal of Clinical Oncology, 1998